ssa retatrutide Reta 5MG Retatrutide clinical trial done! Now
Description
atherosclerosis, heart failure
Other similar products are in early-stage development and could hit the market in 2027 and beyond
Idiopathic central precocious puberty with Prader-Willi syndrome: pubertal development with discontinuation of gonadotropin-releasing hormone analog
Late 2026: Expected submission of New Drug Application (NDA) EarlyMid 2027: Potential FDA approval under standard review timelines This places commercial availability most likely in 2027 , with broader rollout potentially extending into early 2028
lab testing, EHR data including millions of clinical notes
